Beijing Securities 50 drops 0.34%, two stocks from the Beijing Stock Exchange appear on the Dragon and Tiger List, including Keli Shares and Oukang Pharmaceuticals (with list attached)

NightAirdropper · 2026-04-09T18:30:55+00:00

April 7, 2026, the Beijing Securities 50 declined by 0.34%. Keli Co., Ltd. rose by 2.97% and appeared on the top trading list, with a net sell of 52.1957 million yuan; Oukang Pharmaceutical fell by 4.64%, with a net buy of 2.2596 million yuan, both due to a turnover rate exceeding 20%.

NightAirdropper

2026-04-09 18:30:55

Abstract generation in progress

According to Tongbi Finance, on April 7, 2026, the Beijing Stock Exchange 50 Index fell 0.34%, and individual stocks KeLi Co., Ltd. and Oukang Pharmaceuticals listed on the Dragon and Tiger List.

Among them:

KeLi Co., Ltd. (920088) rose 2.97%, closing at 62.00 yuan, with a circulating market value of 2.02B yuan, and a turnover rate of 21.69%. Reason for listing: the top 5 stocks with a turnover rate of 20% on that day. The Dragon and Tiger List bought in 38.2357 million yuan, sold 90.4314 million yuan, with a net buy of -52.1957 million yuan. The top buying seat was East Fortune Securities Co., Ltd. Lhasa East Ring Road Second Securities Business Department, with a buy-in of 8.9313 million yuan; the top selling seat was Guoxin Securities Co., Ltd. Shenzhen Internet Branch, with a sell of 29.2843 million yuan.

Oukang Pharmaceuticals (920230) fell 4.64%, closing at 13.78 yuan, with a circulating market value of 651 million yuan, and a turnover rate of 26.01%. Reason for listing: the top 5 stocks with a turnover rate of 20% on that day. The Dragon and Tiger List bought in 29.1655 million yuan, sold 26.9059 million yuan, with a net buy of 2.2596 million yuan. The top buying seat was Guoxin Securities Co., Ltd. Shenzhen Internet Branch, with a buy-in of 10.8167 million yuan; the top selling seat was Shenwan Hongyuan Securities Co., Ltd. Shanghai Hongkou District Dalian Road Securities Business Department, with a sell of 9.6085 million yuan.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.